Opens in a new tab
Free worldwide shipping
← All research
mTOR & Autophagy Preclinical Study

Inducing Autophagy By Rapamycin Before, But Not After, The Formation Of Plaques And Tangles Ameliorates Cognitive Deficits

Source publication · 2011 · Majumder S, et al.

Research Summary

A mouse study asking whether boosting autophagy with rapamycin can prevent Alzheimer-like pathology in a transgenic model, and whether the same treatment can reverse plaques, tangles and memory loss once they are already established.

Who Or What Was Studied?

3xTg-AD mice, which carry human amyloid precursor protein, presenilin and tau transgenes, plus non-transgenic littermates, on a mixed C57BL6/129svj background: 120 mice in total, 20 per genotype per group. Microencapsulated rapamycin at 14 mg/kg of chow was given either from 2 months of age for 16 months (prophylactic arm) or from 15 months of age for 3 months, after plaques and tangles were already present; controls received the microcapsule diet without drug. All mice were 18 months old at testing and were assessed with the Morris water maze, an object recognition task, immunohistochemistry, ELISA for amyloid-beta, Western blots and electron microscopy.

What Did The Research Show?

  • Both dosing schedules inhibited mTOR in the brain: phosphorylation of p70S6K at Thr389 fell in both treated groups compared with untreated 3xTg-AD mice (p < 0.001), while the autophagy proteins Atg7, Atg5/Atg12 and LC3II rose in both.
  • Lifelong treatment cut thioflavin-S-positive plaques by 52.4% versus untreated controls and 55.6% versus the late-treatment group (p < 0.0001), and lowered soluble amyloid-beta 40 by 52.2% and soluble amyloid-beta 42 by 39.0% versus controls.
  • Only the early-treatment mice improved behaviour: on day 5 of water-maze training their escape latency was 26.9 s versus 37.9 s in untreated 3xTg-AD mice (p < 0.05), and they performed above chance in the object recognition task, while the 15-18 month group performed at chance level.
  • Tau pathology responded the same way: phosphorylation at the AT100 and AT180 epitopes fell significantly in the lifelong group (p = 0.018 and p = 0.0003) but not when rapamycin was started at 15 months.
  • Early treatment also reduced the number of activated CD45-positive microglia in the hippocampus (p = 0.01), whereas late treatment did not, and electron microscopy of the late-treatment mice showed enlarged autophagosomes containing undigested electron-dense material.

Limitations And Interpretation

  • Animal data only: the 3xTg-AD line is a transgenic model of amyloid and tau pathology, so the results cannot be transferred to people with Alzheimer’s disease.
  • One transgenic line, one dietary concentration (14 mg/kg chow) and one start age per arm; there is no dose-response and no measurement of brain rapamycin levels in this experiment.
  • The two arms differed in both start age and duration (16 months versus 3 months), so timing and treatment length are confounded.
  • The authors could not establish whether the reduction in tau phosphorylation is a direct effect of mTOR inhibition or secondary to the fall in amyloid-beta.

Summary prepared from the published paper (abstract and full text where accessible). This is not medical advice — always consult the original publication.

Source: publication record ↗